Sugi Predict

Sugi Predict / Compounds / SCHEMBL689168

SCHEMBL689168

SCHEMBL689168

NS(=O)(=O)c1ccc2c(c1)CC(=O)N2

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 8/20 0.60
▸ SMYD3 Q9H7B4 1/20 0.57
▸ AHR P35869 1/20 0.54
▸ PKM P14618 2/20 0.53
▸ IDO1 P14902 1/20 0.53
▸ CA12 O43570 2/20 0.51
▸ CA1 P00915 2/20 0.51
▸ CA2 P00918 2/20 0.51
▸ CA9 Q16790 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ GRIA1 P42261 1/20 0.49
▸ CACNG8 Q8WXS5 1/20 0.49
▸ PDE3B Q13370 1/20 0.49
▸ PDE3A Q14432 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17980375 0.85 CA12 (0.58) PKMIDO1CA12CA1CA2
SCHEMBL1556955 0.83 GAA (0.60) GAASMYD3AHRPKMIDO1
SCHEMBL2203244 0.83 GAA (0.64) GAASMYD3AHRPKMIDO1
SCHEMBL10293161 0.83 GAA (0.60) GAASMYD3AHRPKMIDO1
SCHEMBL517067 0.83 GAA (0.60) GAASMYD3AHRPKMIDO1
SCHEMBL24247512 0.82 CA12 (0.63) GAAPKMIDO1CA12CA1
SCHEMBL30437651 0.82 SMYD3 (0.64) GAASMYD3AHRPKMIDO1
Hydrochloric Acid SCHEMBL28865546 0.81 GAA (0.62) GAASMYD3AHRPKMIDO1
SCHEMBL6602558 0.80 GAA (0.57) GAASMYD3AHRPKMIDO1
SCHEMBL689464 0.79 GAA (0.56) GAASMYD3AHRPKMIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 — — US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 — — EP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 — — US claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 — — WO claimed
WO-2025064829-A1 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-03-27 — — WO disclosed
US-20230101819-A1 SMYD Inhibitors EPIZYME INC (US) 2023-03-30 — — US disclosed
WO-2021260722-A1 DESIGN, SYNTHESIS OF NOVEL OXYINDOLE INHIBITORS OF DENV RNA DEPENDENT RNA POLYMERASE TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) 2021-12-30 — — WO disclosed
US-20210198252-A1 SMYD INHIBITORS EPIZYME INC (US) 2021-07-01 — — US disclosed
EP-3615080-A1 ANTIBODY CONJUGATES COMPRISING STING AGONIST Novartis AG (CH) 2020-03-04 — — EP disclosed
US-20190322660-A1 SMYD INHIBITORS Epizyme, Inc. 2019-10-24 — — US disclosed
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer Epizyme, Inc. (US) 2019-04-23 — — US disclosed
WO-2018200812-A1 ANTIBODY CONJUGATES COMPRISING STING AGONIST NOVARTIS AG (CH) 2018-11-01 — — WO disclosed
US-5840745-A INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY PHARMACIA S. P. A. (IT) 1998-11-24 — — US disclosed
WO-1998050356-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY SUGEN, INC. (US) 1998-11-12 — — WO disclosed
WO-1997042187-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1997-11-13 — — WO disclosed
US-5663346-A ENZYME INHIBITORS PHARMACIA S.P.A. (IT) 1997-09-02 — — US disclosed
EP-0752985-A1 HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 1997-01-15 — — EP disclosed
WO-1996022976-A1 HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PHARMACIA S.P.A. (IT) 1996-08-01 — — WO disclosed
EP-0715628-A1 SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION PHARMACIA & UPJOHN S.p.A. (IT) 1996-06-12 — — EP disclosed
WO-1996000226-A1 SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION PHARMACIA S.P.A. (IT) 1996-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer SMYD3, SMYD2, SNRPD3 GAA 1822/4885SMYD3 1/4885AHR 1930/4885
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 GAA 714/4885SMYD3 2338/4885AHR 2554/4885
US-20210198252-A1 SMYD INHIBITORS SMYD3, SMYD2, SMURF2 GAA 1370/4885SMYD3 1/4885AHR 2472/4885
US-20190322660-A1 SMYD INHIBITORS SMYD2, SMYD3, SMURF2 GAA 1705/4885SMYD3 2/4885AHR 1942/4885
US-20230101819-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 GAA 1428/4885SMYD3 1/4885AHR 2482/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 GAA 714/4885SMYD3 2338/4885AHR 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.